

**Appendix Table 13. CLOSE-B** (randomization group 1: had no contraindications to PFO closure or oral anticoagulants).

Variable	N	Full Sample	Device	Medication Therapy
<b>Recurrent ischemic strokes (primary outcome), events/N</b>		10/524	0/173	10/351
<b>Age in years , mean (sd)</b>	524	44.25 ( 9.66)	44.13 ( 9.08)	44.31 ( 9.95)
<b>Male Gender</b>	524	295 (56.3%)	96 (55.5%)	199 (56.7%)
<b>White Race</b>	NR			
<b>Smoke</b>	524	153 (29.2%)	52 (30.1%)	101 (28.8%)
<b>Diabetes</b>	524	11 (2.1%)	2 (1.2%)	9 (2.6%)
<b>High Cholesterol</b>	524	66 (12.6%)	20 (11.6%)	46 (13.1%)
<b>Hypertension</b>	524	56 (10.7%)	22 (12.7%)	34 (9.7%)
<b>Prior Stroke</b>	524	19 (3.6%)	8 (4.6%)	11 (3.1%)
<b>Prior Stroke or TIA</b>	524	37 (7.1%)	15 (8.7%)	22 (6.3%)
<b>Atrial Septal Aneurysm</b>	524	172 (32.8%)	53 (30.6%)	119 (33.9%)
<b>Large Sized Shunt<sup>a</sup></b>	524	486 (92.7%)	156 (90.2%)	330 (94.0%)
<b>Presence of a Superficial Infarct<sup>b</sup></b>	524	341 (65.1%)	118 (68.2%)	223 (63.5%)
<b>Index Stroke (vs. TIA)</b>	524	524 (100%)	173 (100%)	351 (100%)

<sup>a</sup>>20 bubbles for all trials except CLOSURE (>25) and CLOSE (>30)..

<sup>b</sup>Not reported in PC Trial.

NR, not reported; SD, standard deviation; TIA indicates transient ischemic attack.